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Purpose/Objective: High risk of tumour regrowth following 
treatment with radiation therapy for a subset of prostate 
cancer patients highlights the need for prognostic 
biomarkers. miRNAs are key regulators of cancer cell 
behavior that could control their response to ionizing 
radiation. Owing to their availability in tissues, serum and 
urine, miRNAs are ideal candidates for the development of 
novel biological tests. This study aimed to identify key 
miRNAs associated with a radioresistant phenotype in cancer 
cells, as a prerequisite for the future development of a novel 
pre-treatment assay for the identification of radiotherapy 
prostate cancer patients at risk of biochemical failure.  
Materials and Methods: A dual approach was used for the 
identification of candidate miRNAs associated with 
radioresistance: (1) an isogenic radiation resistant model was 
generated using the 22Rv1 (primary) prostate cancer (CaP) 
cell line through weekly exposure to 2-Gy fractionated 
ionising radiation. (2) chronically hypoxic 22Rv1 cells (48hrs) 
were used as an additional model for radioresistance. miRNA 
profiling of radioresistant and wild type cells was performed 
using the Exiqon miRCURY array and overlapping 
differentially expressed miRs were identified. 
Results: Following a cumulative total dose of 60Gy, the 
radiation survival curve of the resulting subline RR22Rv1 was 
associated with a significant increase in clonogenic survival 
(1.3 fold increase in survival after 2Gy and 2.2 fold increase 
after 10Gy), when compared to both parent 22Rv1 and aged-
matched controls. The RR22Rv1 cell line is associated with 
decreased sensitivity to DNA damage (comet assay), 
enlargement of the S-phase cell population (PI staining) but 
no evidence for expansion of the senescent cell fraction (β-
Gal assay). miRNA profiling identified 105 significantly 
differentially expressed miRNAs in RR22Rv1, when compared 
to the parent and age-matched control 22RV1 cells. A total of 
12 miRNA were differentially expressed in chronically hypoxic 
compared to normoxic 22Rv1 cells. Three candidate miRNAs 
were associated with a radioresistant phenotype across the 
models: miR200a, miR210 and miR4284. Functional validation 
of these candidates is currently under way.  
Conclusions: This study demonstrates a role for miRNAs in 
the radioresponse of prostate cancer cells and highlights 
their potential for the development of novel prognostic 
biomarkers for radiotherapy prostate cancer patients. 
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Purpose/Objective: Organ preservation of muscle invasive 
bladder cancer after external radiotherapy is an important 
outcome for those patients who are unresectable or chose 
not to have cystectomy. Geometric uncertainties due to 
pelvic organ movement and internal bladder motion present 
a major challenge in defining the true extent of the bladder 
on computerised tomography (CT) images. This is 
complicated further by a lack of soft tissue contrast on CT 
images at the bladder prostate junction (BPJ) where 
significant clinical experience is required to interpret and 
ensure that the dose to the prostate remains within 
acceptable limits. The aim of this study was to investigate 
the use of image analysis for enhancing the BPJ on CT images 
used for RT planning and thereby allow simple image 
thresholding to produce reliable estimates of the clinical 
target volume (CTV). This has application in adaptive 
radiotherapy for automatically defining the bladder volume 
on cone-beam CT (CBCT). 
Materials and Methods: Image data was acquired on a single 
slice General Electric (GE) HiSpeed Fx/i CT scanner (GE 
Medical Systems, Milwaukee, WI, USA) with 0.977 mm pixel 
resolution in the transaxial plane and a 2048 grey-level 
range. Five bladder cancer patients treated with a radiation 
dose of 52.5 Gy (20 fractions/4 weeks) at the Edinburgh 
Cancer Centre (ECC), were included in this study. Each 
patient received a 3 mm thick CT scan, with a presumed 
empty bladder, which was used to: define the target volume; 
define critical anatomical structures; determine the optimum 
radiation beam arrangement; and estimate the dose. Where 
possible CT scanning was performed twice weekly and repeat 
CT scans registered against bone on the corresponding 
planning scan using the GE Advantage fusion software. This 
resulted in 36 data sets, which were contoured by an 
experienced radiation oncologist and image analysis methods 





On the 36 new data sets a threshold was set to extract the 
CTV, which included the bladder and BPJ. The variability 
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(μ±σ) of the volume identified by image analysis on the new 
image sets and by an experienced oncologist on the original 
image sets was 0.76±0.13 measured by the Dice similarity 
criterion (DSC). 17 cases had a DSC above 0.8; 17 cases had a 
DSC between 0.8 and 0.6; 2 cases had a DSC below 0.6. The 
figure shows the CT images from three bladder cancer 
patients. The Blue contour is the CTV; green is the CTV 
produced by thresholding of the original CT images; cyan is 
the CTV produced by thresholding of the image analysis 
enhanced CT image, which shows good agreement with the 
clinical contours using the BPJ-enhanced image data. 
Conclusions: The image analysis study presented for defining 
the CTV on low contrast CT images has the potential to be 
used as part of an adaptive radiotherapy system. Such a 
simple approach was not possible on the original image set. 
Although good agreement was found between the clinical and 
image analysis defined CTV this study serves only to provide 
pilot results. More extensive validation is required using CBCT 
and more observers. 
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Purpose/Objective: Treatment of prostate cancer in frail 
elderly patients is challenging. Many of such patients are not 
candidates for surgery, brachytherapy or SBRT. 
Conventionally fractionated radiotherapy is frequently a 
choice, but duration of such treatment appears as an 
apparent challenge for frail individuals. To address these 
problems we designed a hypofractionated split course 
radiation therapy (HSC-RT) that, potentially, allows 
treatment in reduced number of fractions without 
compromising effectiveness. Because prostate cancer does 
not repopulate rapidly split course RT was allowed. Planned 
interruption may reduce acute reactions and may facilitate 
comfortable outpatient management of patients. 
Materials and Methods: Elderly frail patients with 
intermediate or high risk prostate cancer were considered as 
candidates for the present study. Radiation dose of 62,5 Gy 
in 2.5 Gy per fraction was given over 9 weeks with two 
planned gaps of 14 days each, after accumulation of 25 Gy 
and 50 Gy. Median age of the patients in the analyzed pilot 
series of 20 patients was 76 years (range 67-83), most 
patients had impaired general performance (ZUBROD 1-2) . A 
series of 130 consecutive patients (comparable risk 
characteristics, good PS, median age of 67 years) treated 
with conventionally fractionated radiotherapy (dose of 70-76 
Gy, median 74 Gy) was used for comparison of biochemical 
outcome. Neoadjuvant ADT was used in both groups. PSA 
concentration and treatment tolerance was assessed at 
follow-up. 
Results: In general, HSC-RT was well tolerated, ( the highest 
RTOG score for bladder toxicity during treatment was 1 for 
45% of patients, 2 for 15%, 3 for 5%, rectal toxicity was 
minimal with highest score 1 in 15 % of patients. There were 
not late rectal toxicity and late bladder toxicity was minima 
with highest score 1). Baseline median pretreatment PSA 
concentration was the same in both groups (15 ng/ml). 
However, in spite of planned treatment gaps, the PSA 
measurements at follow-up revealed somewhat favorable 
biochemical outcome in patients treated with HSC-RT, 
compared to those treated conventionally (CF). Median PSA 
concentration (ng/ml) at follow-up was lower in HSC-RT 
compared to CF (0.03 vs. 0.08 at 12 months; 0.03 vs. 0.13 at 
24 months; 0.01 vs. 0.22 at 36 months). Median PSA nadir was 
0.013 ng/ml for HSC-RT vs. 0,03 for CF. 
Conclusions: While the results of this study are limited by a 
small size and clinical heterogeneity of the analyzed group 
the outcome presented suggest that hypofractionated split 
course radiation therapy in frail elderly patients with 
intermediate/high risk prostate cancer is feasible and does 
not compromise biochemical control. 
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Purpose/Objective: Anatomical variation in bladder position 
and size has driven on-line IGART strategies to prevent 
geographical misses. A ‘plan of the day’ IGART approach 
improves target coverage and reduces normal tissue 
irradiation. We report on the clinical outcomes of patients 
treated in a phase 2 study with hypofractionated 
radiotherapy using this technique.  
Materials and Methods: Fifty-five patients with T2-T4aN0-2 
M0 bladder cancer not suitable for cystectomy or daily 
radiotherapy treatment were recruited between February 
2009 and March 2014. A library of 3 plans were created (using 
small, medium and large PTV) from planning CT scans 
performed at 0 and 30 minutes, treating whole (empty) 
bladder to 36Gy in 6 weekly fractions. Cone beam CT (CBCT) 
imaging was performed prior to each fraction. Appropriate 
PTV was selected from the library for treatment delivery. 
Acute toxicity was assessed weekly during radiotherapy and 
at 6 and 12 weeks using CTCAE v3.0. Late toxicity was 
assessed at 6 months and 12 months using Radiation Therapy 
Oncology Group (RTOG) grading. Local control was assessed 
at 3 months preferentially with cystoscopy, or if this was not 
possible with imaging alone (CT/MRI). Local progression free 
